Drug development target; CXXX5-Dvl PPI Diseases; NASH, Diabetes, Obesity, Wound , Hair Loss/Bald, Osteoporosis, Short Stature
Our body maintains homeostasis by the negative feedback regulations of the multiple signaling pathways, and aberrant activation of the negative feedback mechanism results in various diseases by mal-function of signaling pathways.
The Wnt pathway is a route mediating important physiological roles including metabolism, wound healing, hair growth and bone formation. This pathway is especially important for neogenic function by adult stem cells related with the physiological activities.
Aberrant inactivation of the Wnt/beta-catenin signaling by hyper-activation of the negative feedback regulation results in the diseases such as obesity, diabetes, NASH, bald, wound, and osteoporosis.
CK Regeon Inc. identified CXXC5, a negative feedback regulator of the Wnt/beta-catenin pathway function via Dishevelled (Dvl), is overexpressed the diseases and characterized that as a major marker for the diseases and developed the small molecules or peptides blocking the CXXC5-Dvl protein-protein interaction (PPI) as therapeutic agents for curing the diseases.
The aiming drugs which restore Wnt/beta-catenin signaling by blockade of the negative feedback mechanism, especially at the cytoplasm of cells, allow to avoid potential problem of cancer could be caused by aberrant Wnt/beta-catenin signaling activation as well as any side effects could be caused by controlling nuclear functions of CXXC5 as a transcription factor.